



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent  
Licensee of the Blue Cross and Blue Shield Association

## Medical Policy

### Evaluation of Biomarkers for Alzheimer Disease

#### Table of Contents

- [Policy: Commercial](#)
- [Coding Information](#)
- [Information Pertaining to All Policies](#)
- [Authorization Information](#)
- [Policy History](#)
- [References](#)
- [Description](#)

#### Policy Number: 581

BCBSA Reference Number: 2.04.14 (For Plan internal use only)

NCD/LCD: N/A

#### Related Policies

None

#### Policy

##### **Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO Blue<sup>SM</sup> and Medicare PPO Blue<sup>SM</sup> Members**

Cerebrospinal fluid biomarkers testing, including but not limited to amyloid beta peptides, tau protein, or neural thread proteins, as an adjunct to clinical diagnosis in individuals with mild cognitive impairment is considered [INVESTIGATIONAL](#).

Cerebrospinal fluid biomarker testing, including but not limited to amyloid beta peptides, tau protein, or neural thread proteins, as an adjunct to clinical diagnosis in individuals with mild dementia due to Alzheimer disease is considered [INVESTIGATIONAL](#).

Cerebrospinal fluid biomarker testing, including but not limited to amyloid beta peptides, tau protein, or neural thread proteins, as part of an evaluation for the initiation of amyloid beta targeting therapy in individuals with mild cognitive impairment or mild dementia due to Alzheimer disease is considered [INVESTIGATIONAL](#).

Cerebrospinal fluid biomarker testing, including but not limited to amyloid beta peptides, tau protein, or neural thread proteins, as part of an evaluation for the continuation of amyloid beta targeting therapy in individuals with mild cognitive impairment or mild dementia due to Alzheimer disease is considered [INVESTIGATIONAL](#).

Measurement of urinary and blood biomarkers as an adjunct to clinical diagnosis in individuals with mild cognitive impairment or mild dementia due to Alzheimer disease is considered [INVESTIGATIONAL](#).

#### Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

**Outpatient**

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	<b>Outpatient</b>
<b>Commercial Managed Care (HMO and POS)</b>	This is <b>not</b> a covered service.
<b>Commercial PPO and Indemnity</b>	This is <b>not</b> a covered service.
<b>Medicare HMO Blue<sup>SM</sup></b>	This is <b>not</b> a covered service.
<b>Medicare PPO Blue<sup>SM</sup></b>	This is <b>not</b> a covered service.

**CPT Codes / HCPCS Codes / ICD Codes**

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

*Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.*

**The following CPT codes are considered investigational for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:**

**CPT Codes**

<b>CPT codes:</b>	<b>Code Description</b>
0412U	Beta amyloid, Aβ42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology
0443U	Neurofilament light chain (NfL), ultra-sensitive immunoassay , serum or cerebrospinal fluid
0445U	βamyloid (Aβ42) and Phospho Tau (181P) (pTau181), electrochemiluminescence immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology

**Description**

**Alzheimer Disease**

Alzheimer Disease (AD) is a fatal neurodegenerative disease that causes progressive loss in memory, language, and thinking, with the eventual loss of ability to perform social and functional activities in daily life. Survival after a diagnosis of dementia due to AD generally ranges between 4 and 8 years; however, life expectancy can be influenced by other factors, such as comorbid medical conditions. It is estimated that 6.2 million Americans aged 65 and older are currently living with AD dementia, and the number is projected to reach over 12 million by 2050.<sup>1</sup>Per the 2018 American Academy of Neurology practice guideline update on mild cognitive impairment (MCI), the prevalence of MCI was 6.7% for ages 60 to 64, 8.4% for ages 65 to 69, 10.1% for ages 70 to 74, 14.8% for ages 75 to 79, and 25.2% for ages 80 to 84.<sup>2</sup> The cumulative dementia incidence was 14.9% in individuals with MCI >65 years of age followed for 2 years.

Data from the National Institute on Aging have shown that Black Americans are approximately 1.5 to 2 times more likely to develop AD and related dementias as compared to Whites.<sup>3</sup> Additionally, Black participants in AD research studies were 35% less likely to be diagnosed with AD and related dementias and were found to have more risk factors for the disease as well as greater cognitive impairment and symptom severity than White participants. Findings from 2 national surveys conducted by the Alzheimer's

Association also found that people of color face discrimination when seeking health care for AD and related dementias with the highest level of discrimination in dementia health care reported by Black Americans (50%) followed by Native (42%), Asian (34%), and Hispanic (33%) Americans.<sup>4</sup> Non-Hispanic White Americans reported a discrimination rate of 9%.

### Pathophysiology

The pathologic hallmarks of AD are extracellular deposits of amyloid beta, referred to as amyloid plaques, and intracellular aggregates of hyperphosphorylated tau in the form of neurofibrillary tangles. There are different forms of amyloid such as plaques, oligomers, and monomers, and the roles of these different forms and their contributions to the pathophysiology of AD is not well understood. Generally referred to as the “amyloid hypothesis”, it is believed that aggregation of amyloid beta oligomers in the brain leads to amyloid plaques. Amyloid aggregation in addition to accumulation of tau pathology and neurodegeneration are thought to be the main drivers of the disease process. These changes in the brain result in widespread neurodegeneration and cell death, and ultimately cause the clinical signs and symptoms of dementia.<sup>3,4</sup>

The pathophysiological changes and clinical manifestations of AD are progressive and occur along a continuum, and accumulation of amyloid beta may begin 20 years or more before symptoms arise.<sup>5</sup> The National Institute on Aging-Alzheimer’s Association (NIA-AA) has created a “numeric clinical staging scheme” (Table 1) that avoids traditional syndromal labels and is applicable for only those in the Alzheimer continuum. This staging scheme is primarily used in the research setting and reflects the sequential evolution of AD from an initial stage characterized by the appearance of abnormal AD biomarkers in asymptomatic individuals. As biomarker abnormalities progress, the earliest subtle symptoms become detectable. Further progression of biomarker abnormalities is accompanied by progressive worsening of cognitive symptoms, culminating in dementia.

**Table 1. National Institute on Aging-Alzheimer’s Association Numerical Clinical Staging for Individuals in the Alzheimer Continuum<sup>a</sup>**

Stage	Stage 1	Stage 2	Stage 3	Stage 4	Stage 5	Stage 6
Severity	Pre-clinical	Pre-clinical	MCI due to Alzheimer disease	Mild Dementia	Moderate Dementia	Severe Dementia
Clinical Features	Performance within expected range on objective cognitive tests.  No evidence of recent cognitive decline or new neurobehavioral symptoms	Normal performance within expected range on objective cognitive tests.  Transitional cognitive decline (change from individual baseline within past 1 to 3 years, and persistent for at least 6 months).  Mild neurobehavior	Performance in the impaired/abnormal range on objective cognitive tests.  Evidence of decline from baseline.  Performs daily life activities independently, but cognitive difficulty may result in detectable but mild functional impact on the more complex activities of daily life.	Substantial progressive cognitive impairment affecting several domains, and/or neurobehavioral disturbance.  Clearly evident functional impact on daily life, affecting mainly instrumental activities.	Progressive cognitive impairment or neurobehavioral changes.  Extensive functional impact on daily life with impairment in basic activities.  No longer independent and requires frequent assistance	Progressive cognitive impairment or neurobehavioral changes.  Clinical interview may not be possible.  Complete dependency due to severe functional impact on daily life with impairment in basic

		<p>al changes may coexist or may be the primary complaint rather than cognitive.</p> <p>No functional impact on daily life activities.</p>		<p>No longer fully independent /requires occasional assistance with daily life activities.</p>	<p>with daily life activities.</p>	<p>activities, including basic self-care.</p>
--	--	--	--	--	------------------------------------	---

Adapted from Table 6, Jack et al (2018)<sup>6</sup>

<sup>a</sup>Applicable only to individuals in the Alzheimer continuum that fall into 1 of the 4 biomarker groups: 1) A+T+N+ 2) A+T-N- 3) A+T+N- 4) A+T-N+ where A: Aggregated A $\beta$  or associated pathologic state (CSF A $\beta_{42}$ , or A $\beta_{42}$ /A $\beta_{40}$  ratio or Amyloid PET), T: Aggregated tau (neurofibrillary tangles) or associated pathologic state (CSF phosphorylated tau or Tau PET) and N: Neurodegeneration or neuronal injury (anatomic MRI, FDG PET or CSF total tau)

**For stages 1 to 6:** Cognitive test performance may be compared to normative data of the investigator's choice, with or without adjustment (choice of the investigators) for age, sex, education, etc.

**For stages 2 to 6:** Although cognition is the core feature, neurobehavioral changes—for example, changes in mood, anxiety, or motivation—may coexist.

**For stages 3 to 6:** Cognitive impairment may be characterized by presentations that are not primarily amnesic.

CSF: cerebrospinal fluid; FDG: fluorodeoxyglucose; MCI: mild cognitive impairment; MRI: magnetic resonance imaging; PET: positron emission tomography.

### Biomarkers

Several potential biomarkers of AD are associated with AD pathophysiology (eg, amyloid beta plaques, neurofibrillary tangles). Altered cerebrospinal fluid (CSF) levels of specific proteins have been found in patients with AD. These include tau protein, phosphorylated at AD-specific epitopes such as phosphorylated threonine 181 or total tau protein, an amyloid beta peptide such as 1-42 (A $\beta_{42}$ ), and the synaptic protein, neurogranin.<sup>9</sup> Other potential CSF<sup>10,11</sup>, urinary, and blood<sup>12</sup> peptide markers have been explored. Tau protein is a microtubule-associated molecule found in neurofibrillary tangles that are typical of AD. Tau protein is thought to be related to degenerating and dying neurons and high levels of tau protein in the CSF have been associated with AD. Amyloid beta-42 is a subtype of amyloid beta peptide produced from the metabolism of the amyloid precursor protein. Amyloid beta-42 is the key peptide deposited in amyloid plaques characteristic of AD. Low levels of amyloid beta-42 in the CSF have been associated with AD, perhaps because amyloid beta-42 is deposited in amyloid plaques instead of remaining in the fluid. Investigators have suggested the tau/amyloid beta-42 ratio may be a more accurate diagnostic marker than either alone.<sup>13</sup> Neurogranin is a dendritic protein and CSF measurement may serve as a biomarker for dendritic instability and synaptic degeneration.<sup>9</sup> Elevated CSF neurogranin may predict prodromal AD in MCI and has been confirmed in AD dementia and prodromal AD in several studies.

A variety of kits are commercially available to measure amyloid beta-42 and tau proteins. Between-laboratory variability in CSF biomarker measurement is large.<sup>14,15</sup> Neural thread protein is associated with neurofibrillary tangles of AD. Both CSF and urine levels of this protein have been investigated as a potential marker of AD. Urine and CSF tests for neural thread protein may be referred to as the AD7C test.

More recently, research has focused on blood as a new matrix for AD biomarkers that have already been validated in the CSF. As blood is more accessible than CSF, blood sampling would be preferable to CSF when taking samples to measure AD biomarkers, both for clinical diagnosis or screening.<sup>9</sup> However, developing blood AD biomarkers has proven complex. While the CSF is continuous with the brain

extracellular fluid, with a free exchange of molecules from the brain to the CSF, only a fraction of brain proteins enter the bloodstream. Examples of blood biomarkers that are currently under examination for use in AD include amyloid beta, tau protein, and neurofilament light.<sup>16</sup> Results from initial studies show that these blood biomarkers may potentially assist in early and more precise diagnosis, prognosis, or monitoring of disease progression and treatment in AD. In 2019, the Geneva AD Biomarker Roadmap Initiative expert panel concluded that of the currently assessed blood biomarkers plasma pTau has shown analytical validity and initial evidence of clinical validity, whereas the maturity level for amyloid beta remains to be partially achieved.<sup>17</sup>

## Summary

Biochemical changes associated with the pathophysiology of Alzheimer disease (AD) are being evaluated to aid in the diagnosis of AD. This includes the potential use of biomarkers, such as amyloid beta peptide 1-42 and total or phosphorylated tau protein, in cerebrospinal fluid (CSF) urine, and blood. Additionally, the potential correlation between CSF biomarkers and positron emission tomography (PET) amyloid scans may assist in selecting appropriate patients for the initiation or discontinuation of amyloid beta plaque targeted therapy.

### Summary of Evidence

For individuals who have mild cognitive impairment (MCI) or Alzheimer disease (AD) who receive CSF biomarker testing for AD, the evidence includes systematic reviews. These studies assess using CSF biomarkers for diagnosis of AD or for the prognosis of progression of MCI to AD. Relevant outcomes include test validity, correct treatment, avoiding unnecessary subsequent testing, harms of invasive testing, and quality of life (QOL). Most clinical validity studies have been derived from select patient samples and defined optimal test cutoffs without validation; thus, the generalizability of results is uncertain. For predicting conversion from MCI to AD, limited evidence has suggested that testing may define increased risk. Whether an earlier diagnosis leads to improved health outcomes through a delay of AD onset due to medical therapy or other interventions or improved QOL is unknown. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have MCI or AD who receive urinary biomarker testing for AD, the evidence includes a systematic review. Relevant outcomes include test validity, correct treatment, avoiding unnecessary subsequent testing, harms of invasive testing, and QOL. Clinical validity studies have included normal healthy controls and defined optimal test cutoffs without validation; thus, clinical validity is uncertain. Whether an earlier diagnosis leads to improved health outcomes through a delay of AD onset or improved QOL is unknown. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have MCI or AD who receive blood biomarker testing for AD, the evidence includes a systematic review and cohort studies. Relevant outcomes include test validity, correct treatment, avoiding unnecessary subsequent testing, harms of invasive testing, and QOL. Clinical validity studies have primarily focused on the biomarker, plasma pTau, and have shown that this biomarker may be beneficial in screening for and diagnosing AD. Whether an earlier diagnosis leads to improved health outcomes through a delay of AD onset or improved QOL is unknown. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have MCI or mild dementia due to AD who are being considered for initial treatment with an approved amyloid beta plaque targeting therapy, the evidence includes multisite longitudinal studies and an analysis of a mixed cohort. Two of these studies assess the correlation between CSF biomarkers and PET amyloid scans and another assesses the clinical utility of amyloid PET in cognitively impaired patients who met appropriate use criteria for clinical amyloid PET. Relevant outcomes include test validity, symptoms, change in disease status, functional outcomes, health status measures, and QOL. Overall, the diagnostic accuracy of CSF biomarkers versus amyloid PET scans to identify MCI-AD was found to be similar but there are no data to support the clinical utility of CSF biomarker use as a component of determining appropriate initiation of amyloid beta targeting therapy. Prior to the availability of amyloid beta targeting therapy, additional data exist suggesting that amyloid beta PET scan results impacted diagnosis of dementias and patient management including use of symptomatic treatment.

Further research is required to determine whether use of CSF biomarkers alone or in conjunction with amyloid PET scans is associated with improved clinical outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have MCI or mild dementia due to AD, who are being treated with an amyloid beta plaque targeting therapy and are being evaluated for therapy continuation, the evidence includes multisite longitudinal studies and an analysis of a mixed cohort. Two of these studies assess the correlation between CSF biomarkers and PET amyloid scans and another assesses the clinical utility of amyloid PET in cognitively impaired patients who met appropriate use criteria for clinical amyloid PET. Relevant outcomes include test validity, symptoms, change in disease status, functional outcomes, health status measures, and QOL. The diagnostic accuracy of CSF biomarkers versus amyloid beta PET scans to identify MCI-AD was found to be similar. Prior to the availability of amyloid beta targeting therapy, additional data exist suggesting that amyloid beta PET scan results impacted diagnosis of dementias and patient management including use of symptomatic treatment. Further research is required to determine whether use of CSF biomarkers alone in conjunction with amyloid beta PET scans are useful for determining whether or not amyloid beta targeting therapy should be continued. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## Policy History

Date	Action
4/2024	Coding clarified information.
10/2023	Coding clarified information.
12/2022	Annual policy review. The policy statement was updated to further clarify biomarker testing in patients with mild cognitive impairment or dementia due to Alzheimer disease is investigational.
12/2021	Annual policy review. Additional evidence review added for use of CSF biomarkers in the management of MCI or mild dementia due to AD who are being evaluated for the initiation or continuation of amyloid beta targeting therapy. These indications are considered investigational.
2/2021	Annual policy review. Edits made to the second policy statement; intent of policy statements unchanged. Title changed to "Evaluation of Biomarkers for Alzheimer Disease."
1/2020	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
2/2019	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
3/2018	Annual policy review. New references added.
2/2017	Annual policy review. Title changed to "Cerebrospinal Fluid and Urinary Biomarkers of Alzheimer Disease." New references added. 2/1/2017
10/2014	Annual policy review. New references added.
3/2014	New medical policy describing ongoing investigational indications.

## Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

## References

1. 2021 Alzheimer's disease facts and figures. *Alzheimers Dement.* Mar 2021; 17(3): 327-406. PMID 33756057

2. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. Jan 16 2018; 90(3): 126-135. PMID 29282327
3. National Institutes on Aging. Data shows racial disparities in Alzheimer's disease diagnosis between Black and white research study participants. December 16, 2021. <https://www.nia.nih.gov/news/data-shows-racial-disparities-alzheimers-disease-diagnosis-between-black-and-white-research>. Accessed August 24, 2022.
4. Centers for Disease Control and Prevention. Barriers to equity in Alzheimer's and dementia care. June 2, 2021. <https://www.cdc.gov/aging/publications/features/barriers-to-equity-in-alzheimers-dementia-care/index.html>. Accessed August 24, 2022.
5. Alzheimer's Association. 2022 Alzheimer's disease facts and figures. <https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf>. Accessed August 22, 2022.
6. Roberts RO, Aakre JA, Kremers WK, et al. Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. *JAMA Neurol*. Aug 01 2018; 75(8): 970-979. PMID 29710225
7. Vermunt L, Sikkes SAM, van den Hout A, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. *Alzheimers Dement*. Jul 2019; 15(7): 888-898. PMID 31164314
8. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. Apr 2018; 14(4): 535-562. PMID 29653606
9. Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects for the future. *J Intern Med*. Dec 2018; 284(6): 643-663. PMID 30051512
10. Galasko D, Clark C, Chang L, et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. *Neurology*. Mar 1997; 48(3): 632-5. PMID 9065538
11. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. *Ann Neurol*. Oct 1995; 38(4): 643-8. PMID 7574461  
NA
12. Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. *Arch Neurol*. Sep 2003; 60(9): 1202-6. PMID 12975284
13. Dumurgier J, Vercruyse O, Paquet C, et al. Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. *Alzheimers Dement*. Jul 2013; 9(4): 406-13. PMID 23141384
14. Mattsson N, Andreasson U, Persson S, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. *Alzheimers Dement*. Jul 2011; 7(4): 386-395.e6. PMID 21784349
15. Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. *Lancet Neurol*. Jan 2022; 21(1): 66-77. PMID 34838239
16. Ashton NJ, Leuzy A, Karikari TK, et al. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. *Eur J Nucl Med Mol Imaging*. Jul 2021; 48(7): 2140-2156. PMID 33677733
17. Rosa MI, Perucchi J, Medeiros LR, et al. Accuracy of cerebrospinal fluid A(1-42) for Alzheimer's disease diagnosis: a systematic review and meta-analysis. *J Alzheimers Dis*. 2014; 40(2): 443-54. PMID 24448789
18. Bloudek LM, Spackman DE, Blankenburg M, et al. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. *J Alzheimers Dis*. 2011; 26(4): 627-45. PMID 21694448
19. Formichi P, Battisti C, Radi E, et al. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. *J Cell Physiol*. Jul 2006; 208(1): 39-46. PMID 16447254
20. Ferreira D, Perestelo-Perez L, Westman E, et al. Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. *Front Aging Neurosci*. 2014; 6: 47. PMID 24715863
21. Fink HA, Linskens EJ, Silverman PC, et al. Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia. *Ann Intern Med*. May 19 2020; 172(10): 669-677. PMID 32340038

22. Cure S, Abrams K, Belger M, et al. Systematic literature review and meta-analysis of diagnostic test accuracy in Alzheimer's disease and other dementia using autopsy as standard of truth. *J Alzheimers Dis.* 2014; 42(1): 169-82. PMID 24840572
23. Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. *Lancet Neurol.* Jun 2016; 15(7): 673-684. PMID 27068280
24. Ritchie C, Smailagic N, Noel-Storr AH, et al. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). *Cochrane Database Syst Rev.* Mar 22 2017; 3: CD010803. PMID 28328043
25. Ritchie C, Smailagic N, Noel-Storr AH, et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). *Cochrane Database Syst Rev.* Jun 10 2014; (6): CD008782. PMID 24913723
26. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. *Ann Intern Med.* Mar 04 2008; 148(5): 379-97. PMID 18316756
27. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. *BMJ.* Aug 06 2005; 331(7512): 321-7. PMID 16081444
28. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. *Cochrane Database Syst Rev.* Apr 19 2006; (2): CD003154. PMID 16625572
29. Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. *J Intern Med.* Mar 2014; 275(3): 251-83. PMID 24605808
30. Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEX study. *Lancet Neurol.* Jun 2007; 6(6): 501-12. PMID 17509485
31. Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. *Neurology.* May 27 2008; 70(22): 2024-35. PMID 18322263
32. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. *N Engl J Med.* Jun 09 2005; 352(23): 2379-88. PMID 15829527
33. Zhang J, Zhang CH, Li RJ, et al. Accuracy of urinary AD7c-NTP for diagnosing Alzheimer's disease: a systematic review and meta-analysis. *J Alzheimers Dis.* 2014; 40(1): 153-9. PMID 24346218
34. Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. *Nat Med.* Mar 2020; 26(3): 387-397. PMID 32123386
35. Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. *Nat Med.* Mar 2020; 26(3): 379-386. PMID 32123385
36. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA.* Aug 25 2020; 324(8): 772-781. PMID 32722745
37. Jack CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* May 2011; 7(3): 257-62. PMID 21514247
38. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* May 2011; 7(3): 270-9. PMID 21514249
39. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* May 2011; 7(3): 263-9. PMID 21514250
40. Janelidze S, Pannee J, Mikulskis A, et al. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. *JAMA Neurol.* Dec 01 2017; 74(12): 1492-1501. PMID 29114726



41. Hansson O, Lehmann S, Otto M, et al. Advantages and disadvantages of the use of the CSF Amyloid (A) 42/40 ratio in the diagnosis of Alzheimer's Disease. *Alzheimers Res Ther.* Apr 22 2019; 11(1): 34. PMID 31010420
42. Chetelat G, Arbizu J, Barthel H, et al. Amyloid-PET and 18 F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. *Lancet Neurol.* Nov 2020; 19(11): 951-962. PMID 33098804
43. Palmqvist S, Zetterberg H, Mattsson N, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. *Neurology.* Oct 06 2015; 85(14): 1240-9. PMID 26354982
44. Lewczuk P, Matzen A, Blennow K, et al. Cerebrospinal Fluid A42/40 Corresponds Better than A42 to Amyloid PET in Alzheimer's Disease. *J Alzheimers Dis.* 2017; 55(2): 813-822. PMID 27792012
45. Rabinovici GD, Gatsonis C, Apgar C, et al. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. *JAMA.* Apr 02 2019; 321(13): 1286-1294. PMID 30938796
46. Vanderstichele H, Bibl M, Engelborghs S, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. *Alzheimers Dement.* Jan 2012; 8(1): 65-73. PMID 22047631
47. Cordell CB, Borson S, Boustani M, et al. Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. *Alzheimers Dement.* Mar 2013; 9(2): 141-50. PMID 23265826
48. Shaw LM, Arias J, Blennow K, et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. *Alzheimers Dement.* Nov 2018; 14(11): 1505-1521. PMID 30316776
49. Hansson O, Batrla R, Brix B, et al. The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid and tau. *Alzheimers Dement.* Sep 2021; 17(9): 1575-1582. PMID 33788410
50. Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. *Alzheimers Dement.* Jul 31 2022. PMID 35908251
51. Dementia: assessment, management and support for people living with dementia and their carers. National Institute for Health and Care Excellence. Published June 20, 2018. <https://www.nice.org.uk/guidance/ng97>. Accessed August 22, 2022.
52. Cognitive impairment in older adults: screening. U.S. Preventative Task Force. Published February 25, 2020. <https://uspreventiveservicestaskforce.org/uspstf/recommendation/cognitive-impairment-in-older-adults-screening>. Accessed August 22, 2022.